pharmaphorum April 12, 2024
Our regular round-up of financings in the biotech sector features rounds for TORL BioTherapeutics, Nvelop Therapeutics, D3 Bio, and Century Therapeutics.
Antibody-drug conjugate specialist TORL has raised $158 million in a Series B2 financing, led by Deep Track Capital, bolstering its cash reserves as it tries to advance a raft of ADC candidates through clinical testing.
The Los Angeles, California-based biotech’s lead candidate is TORL-1-23, an ADC targeting claudin 6 (CLDN6) that has cleared a phase 1 trial and is en route to a phase 2 study in CLDN6-positive, platinum-resistant ovarian cancer later this year. Following after is TORL-2-307, a CLDN18.2 candidate in early-stage clinical testing in solid tumours, plus two other ADCs targeting CDH17 and DLK1.
A long list...
Today's Sponsors
Today's Sponsor